Clinical drug development process overview MCQs With Answer
This collection of multiple-choice questions is tailored for M.Pharm students to reinforce understanding of the clinical drug development process. It covers key stages from preclinical studies, regulatory filings (IND/CTA), and clinical trial phases I–IV to pivotal trial design, safety monitoring, pharmacovigilance, and accelerated approval pathways. The questions integrate regulatory requirements, trial methodology, statistical and ethical considerations, and post-marketing responsibilities, helping students link theoretical knowledge with practical regulatory expectations. Use these MCQs to evaluate comprehension, prepare for exams, and stimulate deeper study of concepts such as dose escalation, CTD/eCTD submissions, surrogate endpoints, and risk management plans.
Q1. Which document, submitted to regulatory authorities, initiates permission to start clinical trials in humans?
- New Drug Application (NDA)
- Investigational New Drug (IND) application
- Marketing Authorization Application (MAA)
- Clinical Trial Report (CTR)
Correct Answer: Investigational New Drug (IND) application
Q2. Which phase of clinical trials primarily assesses safety, tolerability, and pharmacokinetics in a small number of healthy volunteers or patients?
- Phase II
- Phase I
- Phase III
- Phase IV
Correct Answer: Phase I
Q3. The Common Technical Document (CTD) is structured into modules. Which module primarily contains clinical study reports and trial data?
- Module 1
- Module 2
- Module 3
- Module 5
Correct Answer: Module 5
Q4. Which international guideline defines Good Clinical Practice (GCP) principles for clinical trials?
- ICH E6
- ICH Q1
- ICH M4
- ICH S7
Correct Answer: ICH E6
Q5. In early oncology first-in-human dose escalation, which design is a traditional rule-based method often used to identify the maximum tolerated dose?
- Bayesian adaptive design
- 3+3 design
- Randomized block design
- Cross-over design
Correct Answer: 3+3 design
Q6. Which term describes an unexpected serious adverse reaction that occurs during a clinical trial and must be reported promptly?
- Adverse Event (AE)
- Suspected Unexpected Serious Adverse Reaction (SUSAR)
- Protocol Deviation
- Serious Adverse Event of Expected Nature
Correct Answer: Suspected Unexpected Serious Adverse Reaction (SUSAR)
Q7. Which regulatory pathway is specifically designed to expedite development and review of medicines for serious conditions with preliminary clinical evidence of substantial improvement over existing therapies?
- Fast Track
- Orphan Drug designation
- Standard Review
- Compassionate Use
Correct Answer: Fast Track
Q8. What is the principal objective of a Phase III clinical trial?
- Evaluate long-term pharmacokinetics in healthy volunteers
- Confirm efficacy and monitor adverse reactions in larger patient populations
- Establish proof-of-concept and optimal biological dose in animals
- Conduct post-marketing surveillance of rare events
Correct Answer: Confirm efficacy and monitor adverse reactions in larger patient populations
Q9. In the clinical development dossier, eCTD refers to which of the following?
- an electronic format for regulatory submissions
- a type of clinical endpoint
- an expedited approval designation
- a pharmacovigilance database
Correct Answer: an electronic format for regulatory submissions
Q10. Which committee is responsible for periodic review of accumulating safety data during a clinical trial to recommend continuation, modification, or termination?
- Ethics Committee (IRB/IEC)
- Data Monitoring Committee (DMC) / Data Safety Monitoring Board (DSMB)
- Regulatory Affairs Committee
- Quality Assurance Unit
Correct Answer: Data Monitoring Committee (DMC) / Data Safety Monitoring Board (DSMB)
Q11. A surrogate endpoint is best described as:
- An outcome that directly measures clinical benefit experienced by patients
- A biomarker intended to substitute for a clinical endpoint and predict clinical benefit
- A statistical method to adjust p-values
- A patient-reported satisfaction score
Correct Answer: A biomarker intended to substitute for a clinical endpoint and predict clinical benefit
Q12. Which study design is most appropriate to demonstrate bioequivalence between a generic product and the reference listed drug?
- Double-blind parallel placebo-controlled trial
- Randomized crossover design in healthy volunteers
- Open-label observational cohort
- Adaptive seamless Phase II/III
Correct Answer: Randomized crossover design in healthy volunteers
Q13. What primary purpose does a Risk Management Plan (RMP) serve in regulatory submissions?
- Describe clinical pharmacology and mechanism of action
- Outline identified and potential safety concerns and measures to minimize and monitor risk
- Detail manufacturing process controls
- Provide marketing strategy and labeling claims
Correct Answer: Outline identified and potential safety concerns and measures to minimize and monitor risk
Q14. Which preclinical study type is essential before first-in-human trials to assess potential reproductive toxicity?
- Genotoxicity studies
- Repeat-dose toxicity in rodents
- Carcinogenicity studies
- Reproductive and developmental toxicity studies
Correct Answer: Reproductive and developmental toxicity studies
Q15. Adaptive trial designs allow modifications based on interim data. Which of the following is a common adaptive feature?
- Blinding of investigators only at the end of the study
- Sample size re-estimation based on interim effect estimates
- Removal of informed consent requirements
- Post-marketing labeling changes without evidence
Correct Answer: Sample size re-estimation based on interim effect estimates
Q16. The primary purpose of Phase IV pharmacovigilance activities is to:
- Determine bioavailability in healthy volunteers
- Monitor safety and effectiveness in real-world use and detect rare adverse events
- Establish maximum tolerated dose in humans
- Evaluate immediate toxicology in animals
Correct Answer: Monitor safety and effectiveness in real-world use and detect rare adverse events
Q17. Which statistical concept is essential for calculating the number of participants required to detect a predefined treatment effect with acceptable power?
- Alpha inflation
- Sample size estimation
- Data anonymization
- Randomization stratification
Correct Answer: Sample size estimation
Q18. For medicines intended to treat rare diseases, which regulatory designation provides incentives such as fee reductions and market exclusivity?
- Fast Track
- Breakthrough Therapy
- Orphan Drug designation
- Priority Review
Correct Answer: Orphan Drug designation
Q19. Which element is NOT typically part of an Investigational Medicinal Product Dossier (IMPD)?
- Chemical, pharmaceutical and biological data
- Manufacturing and quality control information
- Nonclinical safety data
- Post-marketing sales forecasts
Correct Answer: Post-marketing sales forecasts
Q20. In multinational trials, a bridging study is performed primarily to:
- Assess cross-cultural validity of patient-reported outcomes
- Support extrapolation of foreign clinical data to a new regional population by evaluating pharmacokinetics and response
- Replace Phase III studies entirely in the new region
- Determine local market price and reimbursement strategy
Correct Answer: Support extrapolation of foreign clinical data to a new regional population by evaluating pharmacokinetics and response
